This article describes the first clinical experience of complete repair of complex critical congenital heart diseases (CHDs) in the first hours of life using autologous umbilical cord blood (UCB). Prenatal diagnosis and harvesting of autologous UCB allow to modify perioperative management and to perform corrective surgery in the first hours of a patient's life. This approach can afford avoiding homologous blood transfusion and preventing development of hypoxemia and heart failure due to hemodynamic changes of complex critical CHD.
The study group included 14 consecutive prenatally diagnosed patients with critical complex CHD during the period from September 2009 to August 2010. Autologous UCB was harvested in accordance to NetCord-FACT International Standards for Cord Blood Collection and was used during the surgery with cardiopulmonary bypass (CPB). In all cases, complete repair was performed during the first hours of life: arterial switch operation (n=9); arterial switch operation with total anomalous pulmonary venous communication repair (n=1); arterial switch operation with interruption of the aortic arch repair (n=1); Ebstein's repair (n=2); and aortopulmonary window repair with interruption of the aortic arch repair (n=1). All procedures were performed using moderate hypothermia with cold-crystalloid cardioplegia, except one case that required deep hypothermic circulatory arrest.
A mean of 92±16 ml of UCB was harvested. Autologous UCB was used during the surgery in all 14 cases. Mean age of newborns at operation was 4.7±2 h (3-8). No patients required intensive care unit (ICU) admission, interventional procedures, mechanical ventilation, or medications before surgery. Twelve patients underwent bloodless open heart surgery; eight of them completely avoided homologous blood transfusion during the perioperative period. There was one postoperative death in our study (Ebstein's anomaly).
The use of autologous umbilical cord blood is feasible in neonatal open heart surgery. Complete surgical repair of complex critical CHD can be applied successfully to neonates within the first hours of life.
[Show abstract][Hide abstract] ABSTRACT: Despite advances in the fields of prevention, medical intervention and surgical therapy, cardiovascular disease remains a major public healthcare issue. A promising area of research is the potential application of regenerative therapies with pluripotential stem cells to reduce the burden of heart disease and its sequelae. Umbilical cord blood, a rich source of multiple populations of nonembryonic stem cells, will be a valuable resource and has the potential to advance therapeutic options for patients with acquired and congenital heart disease.
[Show abstract][Hide abstract] ABSTRACT: In this study, we analyzed our clinical experience performing the arterial switch operation in the first hours of life using autologous umbilical cord blood transfusion (AUCBT). The safety and efficiency of AUCBT was assessed and compared with surgery with the use of homologous blood transfusion.
Between September 2009 and February 2011, 61 neonates underwent ASO at our institution. Patients were enrolled and allocated to two groups with different modalities of management strategies for neonates with dextrotransposition of the great arteries.
The groups were similar in diagnoses, birth weight, cardiopulmonary bypass protocol, and surgical technique, excepting timing of surgery and blood management strategy. Preoperative mean hematocrit did not differ significantly between the groups (45% versus 45%). Mean hematocrit was significantly lower in the study group than in the control group during cardiopulmonary bypass (24% versus 31%). The hematocrit progressively increased in the study group to 38% on the first postoperative day. Serum lactate levels were higher in the study group till the second day after surgery. There were no significant differences in postoperative clinical profiles. There were no hospital deaths and no AUCBT-related side effects in our study.
The arterial switch operation can be performed in the first hours of life with AUCBT. Therefore, AUCBT is a safe and an efficient alternative to homologous blood in neonatal open heart surgery. During the study, we also identified positive economic effects associated with this approach.
The Annals of thoracic surgery 03/2012; 93(5):1571-6. DOI:10.1016/j.athoracsur.2012.01.104 · 3.85 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.